+

WO1999004793A3 - Budipine in the treatment of inflammatory disorders of the nervous system - Google Patents

Budipine in the treatment of inflammatory disorders of the nervous system Download PDF

Info

Publication number
WO1999004793A3
WO1999004793A3 PCT/EP1998/004457 EP9804457W WO9904793A3 WO 1999004793 A3 WO1999004793 A3 WO 1999004793A3 EP 9804457 W EP9804457 W EP 9804457W WO 9904793 A3 WO9904793 A3 WO 9904793A3
Authority
WO
WIPO (PCT)
Prior art keywords
budipine
treatment
nervous system
inflammatory disorders
inn
Prior art date
Application number
PCT/EP1998/004457
Other languages
German (de)
French (fr)
Other versions
WO1999004793A2 (en
Inventor
Thomas Mueller
Reijko Krueger
Wilfried Kuhn
Horst Przuntek
Original Assignee
Byk Gulden Lomberg Chem Fab
Thomas Mueller
Reijko Krueger
Wilfried Kuhn
Horst Przuntek
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Byk Gulden Lomberg Chem Fab, Thomas Mueller, Reijko Krueger, Wilfried Kuhn, Horst Przuntek filed Critical Byk Gulden Lomberg Chem Fab
Priority to AU89765/98A priority Critical patent/AU8976598A/en
Publication of WO1999004793A2 publication Critical patent/WO1999004793A2/en
Publication of WO1999004793A3 publication Critical patent/WO1999004793A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The invention relates to a novel use of the active ingredient budipine (INN) in the treatment of inflammatory disorders of the nervous system.
PCT/EP1998/004457 1997-07-23 1998-07-17 Budipine in the treatment of inflammatory disorders of the nervous system WO1999004793A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU89765/98A AU8976598A (en) 1997-07-23 1998-07-17 Budipine in the treatment of inflammatory disorders of the nervous system

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19731521.6 1997-07-23
DE1997131521 DE19731521A1 (en) 1997-07-23 1997-07-23 Budipin in the treatment of inflammatory diseases of the nervous system

Publications (2)

Publication Number Publication Date
WO1999004793A2 WO1999004793A2 (en) 1999-02-04
WO1999004793A3 true WO1999004793A3 (en) 1999-04-08

Family

ID=7836555

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/004457 WO1999004793A2 (en) 1997-07-23 1998-07-17 Budipine in the treatment of inflammatory disorders of the nervous system

Country Status (3)

Country Link
AU (1) AU8976598A (en)
DE (1) DE19731521A1 (en)
WO (1) WO1999004793A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
YU103003A (en) 2001-06-26 2006-05-25 Abgenix Inc. Antibodies to opgl

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031208A2 (en) * 1995-04-05 1996-10-10 Byk Gulden Lomberg Chemische Fabrik Gmbh Use of substituted piperidine or pyrrolidine compounds for treating sigma-receptor modulated disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031208A2 (en) * 1995-04-05 1996-10-10 Byk Gulden Lomberg Chemische Fabrik Gmbh Use of substituted piperidine or pyrrolidine compounds for treating sigma-receptor modulated disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JACKISCH R ET AL: "THE ANTIPARKINSONIAN DRUGS BUDIPINE AND BIPERIDEN ARE USE -DEPENDENT (UMCOMPETITIVE) NMDA RECEPTOR ANTAGONISTS", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 264, no. 2, 1 January 1994 (1994-01-01), pages 207 - 211, XP000607231 *

Also Published As

Publication number Publication date
WO1999004793A2 (en) 1999-02-04
DE19731521A1 (en) 1999-01-28
AU8976598A (en) 1999-02-16

Similar Documents

Publication Publication Date Title
AU2002234525A1 (en) Transdermal therapeutic system comprising the active ingredient oxybutynin
AU2002361811A1 (en) 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
HUP0000575A3 (en) Novel formulation comprising budesonid as active indegredient
WO2000035919A3 (en) Quinoline derivatives
CA2368843A1 (en) Neurotrophic substituted pyrimidines
HK1027280A1 (en) Plant extracts for the treatment of increased boneresorption.
WO2002041889A3 (en) Indolsulfonyl compounds useful in the treatment of cns disorders
AU8667298A (en) Self-binding shearform compositions
WO1998051348A3 (en) Sustained-release delayed gels
AU2001266152A1 (en) Novel substituted nitrocatechols, their use in the treatment of some central andperipheral nervous system disorders and pharmaceutical compositions containing them
AU2002327097A1 (en) Novel glycolipid and remedial agent for autoimmune disease containing the same as active ingredient
AU2001268422A1 (en) Agmatine and agmatine analogs in the treatment of epilepsy, seizure, and electroconvulsive disorders
CA2192480A1 (en) Benzopyrans and their use as therapeutic agents
WO1998010762A3 (en) Controlled release dosage form of r-(z)-alpha-methoxyimino-alpha-(1-azabicyclo2.2oct-c-yl)acetonitrile monohydrochloride
WO1998027058A3 (en) N-piperazin-1-ylphenyl-benzamide derivatives
AU4806497A (en) Glyoxylic compound comprising one or more active ingredient
WO2001057042A3 (en) 4-pyridyl-and 2,4-pyrimidinyl-substituted pyrrole derivatives and their use in pharmacy
WO1999059523A3 (en) Topical pharmaceutical compositions useful for the treatment of cutaneous or circulatory pathologies on inflammatory, immune, proliferative or degenerative basis
ZA972180B (en) Topical formulations for the treatment of psoriasis of the nail.
WO2000053182A3 (en) 3-cyclopropylmethoxy-4-difluoromethoxy-n-(3,5-dichloropyrid-4-yl)benzamide in the treatment of multiple sclerosis
WO2002046225A3 (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
WO1999004793A3 (en) Budipine in the treatment of inflammatory disorders of the nervous system
AU8269998A (en) Phosphatidylinositol 4,5-bisphosphate 5-phosphatase from human
AU2405297A (en) Cerebral stroke/cerebral edema preventive or remedy containing il-8 binding inhibitor as active ingredient
AU9181298A (en) Gameboard, especially tableboard for ball games

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AU BA BG BR CA CN CZ EE GE HR HU ID IL JP KR LT LV MK MX NO NZ PL RO SG SI SK TR UA US VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AU BA BG BR CA CN CZ EE GE HR HU ID IL JP KR LT LV MK MX NO NZ PL RO SG SI SK TR UA US VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载